

Date: May 19, 2020

| To,  | To,   |
|--|---|
| The Manager,                               | The Department of Corporate Service,        |
| Listing Department,                        | BSE Limited,                                |
| National Stock Exchange of India Limited,  | 1 <sup>st</sup> Floor, New Trading Ring,    |
| Exchange Plaza, C-1, Block-G, Bandra-Kurla | Rotunda Building, Phiroze Jeejeebhoy Tower, |
| Complex, Bandra (E), Mumbai-400 051.       | Dalal Street, Mumbai-400 001.               |
| Scrip Code – LINCOLN                       | Scrip Code – 531633                         |

Dear Sir,

<u>Sub:</u> <u>Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.</u>

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed a Media Release titled on "Lincoln Pharmaceuticals Limited receives European Union (EU) GMP approval".

We request you to kindly take the above on record.

Thanking you,

Yours faithfully,

FOR LINCOLN PHARMACEUTICALS LIMITED

NIREN

ATINBHAI

Digitally signed by NIREN

ATINBHAI DESAI

Date: 2020.05.19


12:34:45 +05'30'

NIREN A. DESAI [COMPANY SECRETARY]

Encl: a/a

Regd. Office: "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India Phone: +91-79-4107 8000 | Fax: +91-79-4107 8062 | CIN L24230GJ1995PLC024288

E-mail: info@lincolnpharma.com | Website: www.lincolnpharma.com











Media Release

## <u>Lincoln Pharmaceuticals Limited receives European</u> <u>Union (EU) GMP approval</u>

To soon enter the EU markets with its Dermatology, Gastro and Pain Management products and expand gradually

## Highlights:-


- EU permission will increase company's business network to 90 plus countries; Currently exports to 60 plus countries;
- Exports have increased to 61% of total sales in FY20 from 11% of total sales in FY11. Company has almost doubled the export turnover in FY20 as compared to FY18.
- Look to expand portfolio in lifestyle & chronic segment especially in Dermatology, Management
- Company has vision to enter the league of 'Top 50 pharma cos' of India in the near future

May 19, 2020: Lincoln Pharmaceuticals Limited, one of India's leading healthcare company has received the European Union (EU) GMP certification from Germany FDA for its manufacturing facility located at Khatraj (Dist: Gandhinagar) in Gujarat. The certification will allow the company to market its products in all the 27 member countries of EU and also give access to European Economic Area (EEA) countries. Company looks to enter the EU markets very soon with its dermatology, gastro and pain management products and gradually expand product portfolio.

The inspection was done by the regulatory agency in December 2019 followed by final approval in May 2020. The company manufactures wide-range of drugs at its Khatraj facility and includes anti-infective, respiratory system, gynaecology, dermatology, gastro, pain management, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others.

Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, "We are very pleased and excited to receive the EU GMP accreditation. This will be an important stepping stone in the journey of the company and will help to expand its presence in more regulated markets. The approval is valid for all three departments Tablet, Capsule and Cream & Ointment, which will cover wide range of Pharmaceutical Formulation manufactured by the Company. EU GMP approval is the result of stringent quality and compliance norms followed at Lincoln Pharma across all departments especially the R&D and compliance. The certification will allow us to address the growing needs of patients in the EU markets and provide affordable and innovative medicines."

Regd. Office: "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India Phone: +91-79-4107 8000 | Fax: +91-79-4107 8062 | CIN L24230GJ1995PLC024288











With the EU certification, company will expand its business network to 90 plus countries. Company currently exports to 60 plus countries including East & West Africa, Central & Latin America and Southeast Asia and has got many product registrations in these countries and is also awarded with number of global tenders.

Export business has shown remarkable growth in the last few years. Exports have increased to 61% of total sales in FY20 from 11% of total sales in FY11. Company has almost doubled the export turnover in FY20 as compared to FY18. Export of the company stood at Rs. 227 crore in FY20 as compared to Rs. 197 crore in FY19, a growth of 15% Y-O-Y.

"Over the years, company has seen good traction in the export business, which is expected to get further boost once EU operations begins. For the next phase of growth, company is building a strong portfolio in lifestyle and chronic segment especially dermatology, gastro and pain management to complement its strong presence in acute segment. Strategic growth initiatives, EU approval, new product approvals, better margin products along with operational efficiency are likely to contribute healthy growth and maximize value for all stakeholders in the near to medium term," said Mr. Patel.

Lincoln Pharmaceuticals Limited has developed 300 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. Company has filled 20 plus patent applications and is awarded five patents. Company's manufacturing facilities fulfills the cGMP guidelines and abides with WHO, cGMP norms and are certified by WHO GMP and ISO 9001:2015 along with approvals from many Countries. Company have its strong presence in Domestic market with good strength of own field force.

About Lincoln Pharmaceuticals Limited: https://www.lincolnpharma.com/

## Providing Affordable and Innovative medicines for healthier lives.

Lincoln Pharmaceuticals Limited is one of the leading healthcare companies in Gujarat, India. Established in the year 1979, the company develops and manufactures affordable and innovative medicines for healthier lives. The company has developed 300 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. The company have its strong presence in Domestic market with good strength of own field force and also exports to more than 60 Countries.

Company has developed many new drug delivery dosage forms over years and has a track record of launching many first-of-its-kind innovative products. Company works with a vision for nurturing innovations and bringing them to Indian patients at an affordable cost to create "Healthcare for All".

Regd. Office: "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India Phone: +91-79-4107 8000 | Fax: +91-79-4107 8062 | CIN L24230GJ1995PLC024288

E-mail: info@lincolnpharma.com | Website: www.lincolnpharma.com









Lincoln Pharmaceuticals Limited has a state-of-the-art manufacturing facility unit at Khatraj (Dist: Gandhinagar) in Gujarat, complying with stringent international quality and compliance norms and certified by WHO-GMP and ISO-9001: 2015. Recently company has also received European Union (EU) GMP certification for its manufacturing facility which will allow it to market its products in all the 27 member countries of EU and also give access to European Economic Area (EEA) countries. Company is engaged in manufacturing of pharma formulations like Tablets, Capsules, Injectables, Syrups, Ointments, etc.

Company's key strength is embedded in its cutting-edge research and development capabilities. The company has a strong R&D team including 30 plus scientists. It has filled 20 plus patent applications and is awarded five patents. R&D center of the company is recognised by the Department of Scientific and Technology, Government of India and furnished with state-of-the-art devices and equipment for internal physical, chemical and microbiological analysis of all products.

Going green, company has also set up a new Solar Plant of 1 MW at factory's rooftop with a capacity of producing 15 Lakh Power Unit Per annum in addition to two windmills. This way we are producing renewable energy to our consumption nearly 65% resulting significant saving in the electricity cost and helped the company to become a self-sustainable and environment-friendly organization. Company's long term ratings are revised from A-/stable to A-/positive and short term rating A2+by ICRA.

## Safe Harbor Statement

This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Company expressly disavows any obligation to update the information presented in this release.

Regd. Office: "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India Phone: +91-79-4107 8000 | Fax: +91-79-4107 8062 | CIN L24230GJ1995PLC024288

E-mail: info@lincolnpharma.com | Website: www.lincolnpharma.com





